Last reviewed · How we verify
COVID-19 vaccine, high dose level — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
COVID-19 vaccine, high dose level (COVID-19 vaccine, high dose level) — Rokote Laboratories Finland Oy.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| COVID-19 vaccine, high dose level TARGET | COVID-19 vaccine, high dose level | Rokote Laboratories Finland Oy | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- COVID-19 vaccine, high dose level CI watch — RSS
- COVID-19 vaccine, high dose level CI watch — Atom
- COVID-19 vaccine, high dose level CI watch — JSON
- COVID-19 vaccine, high dose level alone — RSS
Cite this brief
Drug Landscape (2026). COVID-19 vaccine, high dose level — Competitive Intelligence Brief. https://druglandscape.com/ci/covid-19-vaccine-high-dose-level. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab